The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Garrison, Louis P., Wang, Si-Tien, Huang, Hui, Ba-Mancini, Abbie, Shi, Hongliang, Chen, Kristina, Korves, Caroline, Dhawan, Ravinder, Cakana, Andrew, van de Velde, Helgi, Corzo, Deyanira, Duh, Mei Sheng
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2013
Soggetti:
Economics of Oncology Practice
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556252/
https://ncbi.nlm.nih.gov/pubmed/23299777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0380
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi